1. Ability to provide written informed consent. <br/ > 2. Participants of either gender of age �18 years. <br/ > 3. Received and completed Coronavirus Disease 2019 vaccine under Emergency Use <br/ > Authorization (EUA) dosing guidelines at least 6 ± 1month (after receipt of second dose of EUA <br/ > vaccine) prior to enrollment, confirmed by the electronic Covid-19 Certificate (CoWIN). <br/ > 4. Expressed interest and availability to fulfill the study requirements. <br/ > 5. For a female participant of child-bearing potential, planning to avoid becoming pregnant <br/ > (use of an effective method of contraception or abstinence) from the time of study enrolment until at <br/ > least four weeks after vaccination <br/ > 6. Agrees not to participate in another clinical trial at any time during the study period. <br/ > 7. Agrees to remain in the study area for the entire duration of the study. <br/ > 8. Willing to allow storage and future use of biological samples for future research

1. Ability to provide written informed consent. <br/ > 2. Participants of either gender of age �18 years. <br/ > 3. Received and completed Coronavirus Disease 2019 vaccine under Emergency Use <br/ > Authorization (EUA) dosing guidelines at least 6 ± 1month (after receipt of second dose of EUA <br/ > vaccine) prior to enrollment, confirmed by the electronic Covid-19 Certificate (CoWIN). <br/ > 4. Expressed interest and availability to fulfill the study requirements. <br/ > 5. For a female participant of child-bearing potential, planning to avoid becoming pregnant <br/ > (use of an effective method of contraception or abstinence) from the time of study enrolment until at <br/ > least four weeks after vaccination <br/ > 6. Agrees not to participate in another clinical trial at any time during the study period. <br/ > 7. Agrees to remain in the study area for the entire duration of the study. <br/ > 8. Willing to allow storage and future use of biological samples for future research